Cerus (NSDQ:CERS) said today that it exercised $46.6 million in additional options from its contract with the Biomedical Advanced Research & Development Authority, a part of the U.S. Dept. of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response.
Concord, Calif.-based Cerus is developing the Intercept blood system, a pathogen reduction device designed to inactivate a broad range of viruses, bacteria, parasites and leukocytes in donated blood. The company plans to use its newly-acquired funds to support the Phase III ReCePI study and a UK trial evaluating Intercept red blood cells in sickle cell disease patients undergoing exchange transfusion.
Get the full story at our sister site, Drug Delivery Business News.